Investigation of the Proportion of Human Epidermal Growth Factor Receptor 2 Protein Overexpression of Gastric Adenocarcinoma and Prognostic Effect of HER2, and Analysis of Practice Pattern of Herceptin Use in Stage IV Gastric Cancer
NCT ID: NCT02136836
Last Updated: 2014-05-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
860 participants
OBSERVATIONAL
2014-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
HER2 Circulating Tumor Cells in Gastric Cancer
NCT01299688
Evaluation of HER2-targeted Therapy for Gastric Cancer and Establishment and Verification of Monitoring System
NCT05165602
An Observational Study of Herceptin (Trastuzumab) in Patients With HER2-positive Advanced Gastric Cancer
NCT01220934
Clinical Study to Evaluate the Safety and Anti-Tumor Activity of AB-201
NCT07333820
Pembrolizumab, Trastuzumab, HER2 Positive Gastric Cancer
NCT02901301
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
gastric adenocarcinoma
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients were diagnosed during 2006-2013
3. HER2 expression status was evaluated in primary gastric cancer or metastatic lesion.
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yonsei University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jae Yong Cho
Chief of division of medical oncology, Gangnam Severance Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jae Yong Cho, M.D.,Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Gangnam Severance Hospital, Yonsei University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Gangnam Severance Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Roche
Identifier Type: OTHER
Identifier Source: secondary_id
GSCH-STO13-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.